Seed Biotech & Computational Therapeutics Pitch Deck Benchmarks
Startup benchmarks for Seed Biotech & Computational Therapeutics: Median Burn Multiple (1x), Gross Margin (77%), and Startup Health Score (71.8/100) across 4,686 real companies.
Audit Your Pitch Deck Before VCs See It
Check your burn multiple, unit economics, and capital efficiency against 4,686 real Seed Biotech & Computational Therapeutics startups in 20 minutes.
Upload Pitch Deck for Free Audit →| Metric | P25 (Bottom 25%) | Median (50th) | P75 (Top 25%) | P90 (Top 10%) |
|---|---|---|---|---|
| Startup Health & Survivability Score (0-100) | 65.2 | 71.8 | 72.7 | 73.2 |
| Gross Profit Margin (%) | 73% | 77% | 81% | 84% |
| Burn Multiple (Net Burn ÷ Net ARR) | 0.7x | 1x | 1.3x | 1.5x |
| Rule of 40 (Growth + Profit Margin) | 34 | 45 | 56 | 62 |
Verified statutory sample: 4,686 companies • Quorum requirement: N ≥ 25 • Updated: 2026-11-05
Frequently Asked Due Diligence Questions
What is a healthy burn multiple for a Seed Biotech & Computational Therapeutics startup?
Across 4,686 verified companies, the median burn multiple is 1x. Startups in the top 25th percentile (most capital-efficient) operate at 0.7x or lower.
What startup health and survivability score do investors expect at Seed?
The median startup health score is 71.8 out of 100. Top quartile companies reach 72.7 or higher before entering partner meetings.
How can I audit my pitch deck before pitching venture capital investors?
Founders can run an automated 20-minute pitch deck audit on EstiloFlow Vantage to stress-test unit economics, cash burn, and cap table dilution against real-world sector standards.